Drugs / PPS vaccine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06015308 Background | Oct 2023 → Oct 2025 | atopic eczema | Sanofi | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PPS vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06015308 ↗ |
| Known as | Pneumovax 23 | “Pneumovax 23 (PPSV)” NCT06015308 ↗ |
| Known as | PPSV | “Pneumovax 23 (PPSV)” NCT06015308 ↗ |
| Route | Intramuscular | “Intramuscular or subcutaneous injection into the deltoid muscle of the upper arm” NCT06015308 ↗ |
| Route | Subcutaneous | “Intramuscular or subcutaneous injection into the deltoid muscle of the upper arm” NCT06015308 ↗ |